8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2003

DaVita Inc.

(Exact name of registrant as specified in its charter)

Delaware	1-4034	51-0354549
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
21250 Hawthorne Boulevard, Suite 800, Torrance, California		90503
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (310) 792-2600

Item 5.    Other Events and Regulation FD Disclosure

The Registrant announced today that its wholly-owned subsidiary, Renal Treatment Centers, Inc. (“RTC”), issued a notice of redemption with respect to all of its outstanding 5 5/8% Convertible Subordinated Notes due 2006 (the “Notes”). Attached hereto as Exhibit 99.1 is a press release announcing the redemption of the Notes by RTC issued on June 19, 2003, which is incorporated by reference herein.

Item 7.    Financial Statements and Exhibits.

(c)  Exhibits

Exhibit No.	Description
99.1	Press Release, dated June 19, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2003 DAVITA INC. /s/    PATRICK BRODERICK Patrick Broderick Vice President, Secretary and General Counsel

EX-99.1

EXHIBIT 99.1

Contact: LeAnne Zumwalt Investor Relations DaVita Inc. 310 750-2072

DAVITA INC. CALLS FOR REDEMPTION OF

5 ⁵/8% CONVERTIBLE SUBORDINATED NOTES

TORRANCE, CA, June 19, 2003 — DaVita Inc. (NYSE: DVA) today announced that Renal Treatment Centers, Inc., its wholly-owned subsidiary, is calling for redemption of its 5 ⁵/8% Convertible Subordinated Notes due 2006 (the “Notes”) as of July 15, 2003. The aggregate principal amount outstanding of the Notes is $125 million. The CUSIP number for the Notes is 759671AC4.

Prior to 5:00 p.m., Philadelphia time, on July 14, 2003, holders may convert their Notes into shares of DaVita common stock at a price of $25.62 per share. Any Notes not converted on or before 5:00 p.m., Philadelphia time, on July 14, 2003, automatically will be redeemed on July 15, 2003, and no further interest will accrue. Upon redemption, holders will receive a total of $1,016.90 per $1,000 principal amount of Notes.

A Notice of Redemption is being sent to all registered holders of the Notes. Copies of the Notice of Redemption may be obtained from JP Morgan Trust Company National Association by calling bondholder inquiry services at 1-800-275-2048.

DaVita is a leading provider of dialysis services for patients suffering from chronic kidney failure. The Company owns and operates kidney dialysis centers and home peritoneal dialysis programs domestically in 33 states, as well as Washington, D.C. As of March 31, 2003, DaVita operates 523 outpatient facilities serving 45,000 patients, including 3,300 patients in 30 centers under management.